Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkEffect of Nivolumab vs Bevacizumab in Patients with Recurrent Glioblastoma

In this Original Investigation, JAMA Oncology explores the CheckMate 143 Phase 3 trial, asking whether PD-1 immune checkpoint inhibition with nivolumab improves overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form